These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16001645)

  • 61. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment.
    Agnholt J; Kelsen J; Brandsborg B; Jakobsen NO; Dahlerup JF
    Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):649-55. PubMed ID: 15201577
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
    Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
    Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Increased cell proliferation characterizes Crohn's disease.
    Noffsinger A; Unger B; Fenoglio-Preiser CM
    Mod Pathol; 1998 Dec; 11(12):1198-203. PubMed ID: 9872652
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms.
    Lupascu A; Armuzzi A; De Pascalis B; Carloni E; Lauritano EC; Gasbarrini A; Pola P; Gasbarrini A
    Dig Liver Dis; 2004 Jun; 36(6):423-5. PubMed ID: 15248384
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Anti-Saccharomyces cerevisiae antibodies and response to infliximab in refractory Crohn's disease.
    Schröder O; Naumann M; Stein J
    Aliment Pharmacol Ther; 2004 Oct; 20(7):823-4. PubMed ID: 15379845
    [No Abstract]   [Full Text] [Related]  

  • 66. Are there predictors of Remicade treatment success or failure?
    Su C; Lichtenstein GR
    Adv Drug Deliv Rev; 2005 Jan; 57(2):237-45. PubMed ID: 15555740
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
    Arijs I; Quintens R; Van Lommel L; Van Steen K; De Hertogh G; Lemaire K; Schraenen A; Perrier C; Van Assche G; Vermeire S; Geboes K; Schuit F; Rutgeerts P
    Inflamm Bowel Dis; 2010 Dec; 16(12):2090-8. PubMed ID: 20848504
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab.
    Carpenter E; Jackson MA; Friesen CA; Scarbrough M; Roberts CC
    J Pediatr; 2004 Apr; 144(4):541-4. PubMed ID: 15069408
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mucosal healing in pediatric Crohn's disease: the goal of medical treatment.
    D'Haens G
    Inflamm Bowel Dis; 2004 Jul; 10(4):479-80. PubMed ID: 15475761
    [No Abstract]   [Full Text] [Related]  

  • 70. Infliximab and the bone in Crohn's disease.
    Kunisaki R; Chaki O; Taguchi T; Sugiyama T; Sugita A
    Aliment Pharmacol Ther; 2005 Mar; 21(6):789-90. PubMed ID: 15771766
    [No Abstract]   [Full Text] [Related]  

  • 71. [Selective TNF-alpha inhibition in Crohn disease. Emergency help in problem cases].
    MMW Fortschr Med; 2001 May; 143(18):52. PubMed ID: 11387713
    [No Abstract]   [Full Text] [Related]  

  • 72. Does active Crohn's disease have decreased intestinal antioxidant capacity?
    Pinto MA; Lopes MS; Bastos ST; Reigada CL; Dantas RF; Neto JC; Luna AS; Madi K; Nunes T; Zaltman C
    J Crohns Colitis; 2013 Oct; 7(9):e358-66. PubMed ID: 23523266
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Profoundly Expanded T-cell Clones in the Inflamed and Uninflamed Intestine of Patients With Crohn's Disease.
    Doorenspleet ME; Westera L; Peters CP; Hakvoort TBM; Esveldt RE; Vogels E; van Kampen AHC; Baas F; Buskens C; Bemelman WA; D'Haens G; Ponsioen CY; Te Velde AA; de Vries N; van den Brink GR
    J Crohns Colitis; 2017 Jul; 11(7):831-839. PubMed ID: 28158397
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Probe-based confocal laser endomicroscopy: a new method for quantitative analysis of pit structure in healthy and Crohn's disease patients.
    Musquer N; Coquenlorge S; Bourreille A; Aubert P; Matysiak-Budnik T; des Varannes SB; Lauwers G; Neunlist M; Coron E
    Dig Liver Dis; 2013 Jun; 45(6):487-92. PubMed ID: 23466186
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Successful infliximab therapy for oral Crohn's disease.
    Cardoso H; Nunes AC; Carneiro F; Tavarela Veloso F
    Inflamm Bowel Dis; 2006 Apr; 12(4):337-8. PubMed ID: 16633058
    [No Abstract]   [Full Text] [Related]  

  • 76. Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease.
    Rosenstiel P; Agnholt J; Kelsen J; Medici V; Waetzig GH; Seegert D; Schreiber S
    Gut; 2005 Feb; 54(2):314-5; author reply 316-6. PubMed ID: 15647208
    [No Abstract]   [Full Text] [Related]  

  • 77. [Pathologic aspects of Crohn's disease of the colon. Apropos of 3 cases].
    Albot G; Camilleri JP; Parturier-Albot M
    Sem Hop; 1969 Dec; 45(52):3307-17. PubMed ID: 4312632
    [No Abstract]   [Full Text] [Related]  

  • 78. Perianal Crohn's disease (Br J Surg 2004; 91: 801-814).
    Olaison G; Almer S; Anderson P
    Br J Surg; 2004 Oct; 91(10):1381. PubMed ID: 15382098
    [No Abstract]   [Full Text] [Related]  

  • 79. Confocal laser endomicroscopy: a novel method for prediction of relapse in Crohn's disease.
    Karstensen JG; Săftoiu A; Brynskov J; Hendel J; Klausen P; Cârtână T; Klausen TW; Riis LB; Vilmann P
    Endoscopy; 2016 Apr; 48(4):364-72. PubMed ID: 26583952
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Gene therapy with interleukin 10 in Crohn's disease: too early yet].
    Dijkstra G; Hospers GA; Kleibeuker JH
    Ned Tijdschr Geneeskd; 2003 Nov; 147(44):2153-6. PubMed ID: 14626830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.